Nkarta wins FDA nod for outpatient dosing in NKX019 autoimmune trials

• Nkarta reached FDA agreement to amend Ntrust-1 and Ntrust-2 trials to enable outpatient dosing of investigational CAR-NK therapy NKX019, expanding access to community rheumatology centers.
• Protocol changes cut required post-dose monitoring to 2 hours from 24 hours, reducing patient burden and supporting broader trial-site participation.
• Trial design now allows optional re-dosing in both studies to support response optimization.
• Ntrust-2 will add a rheumatoid arthritis cohort once protocol amendments clear FDA submission and IRB review, widening the autoimmune disease focus.
• Initial data from ongoing dosing at 4 billion cells per dose are expected to be presented at a medical meeting later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604151601PRIMZONEFULLFEED9690338) on April 15, 2026, and is solely responsible for the information contained therein.